Immutep (NASDAQ:IMMP) Shares Pass Below Fifty Day Moving Average – What’s Next?

Immutep Limited (NASDAQ:IMMP)’s share price passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $2.01 and traded as low as $1.87. Immutep shares last traded at $1.89, with a volume of 67,807 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird upped their price target on shares of Immutep from $6.00 to $7.00 and gave the stock an “outperform” rating in a report on Friday, November 15th.

Immutep Trading Down 1.6 %

The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.25 and a current ratio of 18.25. The stock has a 50 day moving average price of $2.01 and a 200 day moving average price of $2.10.

Institutional Investors Weigh In On Immutep

Hedge funds have recently added to or reduced their stakes in the business. ABC Arbitrage SA bought a new position in shares of Immutep during the fourth quarter valued at $152,000. XY Capital Ltd raised its position in Immutep by 108.3% during the 3rd quarter. XY Capital Ltd now owns 108,349 shares of the biotechnology company’s stock worth $239,000 after purchasing an additional 56,344 shares during the last quarter. Two Sigma Securities LLC acquired a new position in Immutep during the 4th quarter worth about $74,000. Meridian Wealth Management LLC grew its position in shares of Immutep by 4.5% in the 3rd quarter. Meridian Wealth Management LLC now owns 398,450 shares of the biotechnology company’s stock valued at $881,000 after buying an additional 17,250 shares during the last quarter. Finally, OLD Mission Capital LLC acquired a new stake in shares of Immutep in the fourth quarter valued at about $36,000. 2.32% of the stock is currently owned by institutional investors and hedge funds.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.